ETC
CHRS icon

Exchange Traded Concepts’s Coherus Oncology CHRS Stock Holding History

Exchange Traded Concepts’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-32,659
Closed -$452K – 1128
2021
Q2 		$452K Buy
32,659
+3,400
+12% +$48.1K 0.01% 660
2021
Q1 		$427K Buy
+29,259
New +$497K 0.02% 615

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Exchange Traded Concepts's CHRS Position: Q3 2021 in Review

Exchange Traded Concepts sold out of Coherus Oncology (CHRS) in Q3 2021, closing a stake of 32,659 shares — an estimated $452K sold.

Exchange Traded Concepts first reported a position in CHRS in Q1 2021 and held it in 2 quarters. The position peaked at $452K in Q2 2021. 187 funds tracked by Wall St. Rank hold CHRS as of Q3 2021.

  • Exchange Traded Concepts reported no remaining Coherus Oncology position as of Q3 2021 after selling out during the quarter.
  • Exchange Traded Concepts sold 32,659 Coherus Oncology shares in Q3 2021, an estimated $452K.
  • Exchange Traded Concepts first reported a position in Coherus Oncology in Q1 2021 and held it in 2 quarters.
  • Exchange Traded Concepts's Coherus Oncology position peaked at $452K in Q2 2021.
  • 187 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2021.

Based on Exchange Traded Concepts's 13F filing for Q3 2021, filed 18 Oct 2021.